title: Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life.
abstract: This article reviews the symptoms and everyday problems associated with tamoxifen adjuvant therapy and their impact on patients' quality of life. In addition, the purported toxic effects of tamoxifen therapy (e.g., premature menopause, weight gain, and depression) are discussed, and data are presented that refute claims of the toxicity of tamoxifen therapy. From randomized controlled trials of adjuvant therapy, we know that tamoxifen therapy increases the rate of hot flashes, night sweats, and vaginal discharge; however, in observational studies these symptoms do not have a statistically significant impact on patients' quality of life as measured by standardized, self-report questionnaires. The Breast Cancer Prevention Trial found no evidence of excessive rates of depression or clinically significant differences in sexual functioning between women receiving placebo and those receiving tamoxifen therapy. Although several serious medical risks from tamoxifen therapy exist (e.g., uterine cancer, blood clots, stroke, and cataracts), there are additional benefits from tamoxifen therapy in addition to an increase in disease-free survival rates and overall survival rates, including a decrease in contralateral breast cancer and fractures. Ultimately, the decision to receive tamoxifen therapy is a personal choice for each woman to make on the basis of the evidence of tamoxifen therapy's benefits and risks, along with her own motivation to receive therapy. When the benefits of such therapy are small, some women may choose to avoid treatment, but others may wish to try therapy to determine whether possible side effects are relevant. For women in whom the absolute survival benefits are large, there may be less difficulty in making this decision.
authors.affiliation: Division of Cancer Prevention and Control Research, Jonsson Comprehensive Cancer Center at University of California-Los Angeles, Box 956900, Rm. A2-125 CHS, Los Angeles, CA 90095-6900, USA. pganz@ucla.edu
authors.forename: P A
authors.initials: PA
authors.lastname: Ganz
mesh_terms: D000367:Age Factors; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000534:rehabilitation; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008594:Menopause, Premature; D008875:Middle Aged; D011788:Quality of Life; D012307:Risk Factors; D019529:Sexuality / Q000187:drug effects; D013629:Tamoxifen / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use*; D015430:Weight Gain / Q000187:drug effects
chemical_list: D013629:Tamoxifen